Navigation Links
UCB, Inc. Resolves Investigation of Past Keppra® Marketing and Promotional Activities
Date:6/9/2011

ATLANTA, June 9, 2011 /PRNewswire/ -- UCB, Inc. today announced an agreement with the U.S. Department of Justice (DOJ) to resolve a previously disclosed government investigation into the marketing and promotion of Keppra®, an anti-epileptic prescription medicine. As previously reported, the issues that were the subject of this investigation occurred more than six years ago, and as recognized by the DOJ, UCB has cooperated fully with the United States since learning of the investigation in 2008.

Under the agreement, UCB pled guilty to a single misdemeanor violation and agreed to pay USD 8.6 million under the Federal Food, Drug and Cosmetic Act.  UCB also entered into a separate civil settlement agreement and will pay USD 25.8 million plus modest interest to the United States and State Medicaid programs to resolve allegations relating to the False Claims Act. As with many other pharmaceutical settlements, UCB also agreed to enter into a five-year corporate integrity agreement (CIA) with the Office of Inspector General of the U.S. Department of Health and Human Services.

This CIA builds upon and requires the maintenance of UCB's existing compliance program. The commitments in the CIA are also consistent with UCB's previously stated commitment to comply with the laws and regulations that govern the pharmaceutical industry as evidenced last year by the company's voluntary public certification to adhere to PhRMA's Code on Interactions with Healthcare Professionals.

"UCB takes compliance with all applicable laws, policies, and procedures very seriously and remains committed to the highest standards of corporate conduct," said Greg Duncan, UCB's President for North American Operations. "We have worked diligently over the years to enhance our compliance program and we continue to evolve our compliance efforts to meet the changing demands of the regulatory environment in which we operate. We are pleased to have resolved this matter and look forward to continuing to work with the many organizations with whom we partner to advance our mission of transforming the lives of people living with severe diseases."

About UCB, Inc.
UCB Inc., is a Delaware corporation. Its parent company, UCB S.A., is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing approximately 8,500 people in more than 40 countries, UCB generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statement
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.

For further information
Kristie Madara, U.S. Corporate Communications
(770) 970-8726, kristie.madara@ucb.com

Nancy Nackaerts, Global External Communications
+32 473 86 44 14, nancy.nackaerts@ucb.com

Antje Witte, Investor Relations
+32 2 559 94 14, antje.witte@ucb.com


'/>"/>
SOURCE UCB, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities
2. Amgen Resolves EPO Patent Dispute With Roche
3. New Study Reports That Physical Therapy Treatment Resolves Symptoms of Urinary Incontinence in Women
4. Morphotek, Inc. Announces That Two Investigational Drugs Have Received Orphan Drug Designations
5. Bayers Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone
6. Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC
7. Bayer to Present Data on Investigational Oncology Compounds at 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)
8. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
9. Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
10. Investigational Drug May Reduce Involuntary Movements in People With Parkinsons Disease
11. Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , Dec. 7, 2016   IQuity, Inc., ... that Don Hardison has been ... an executive with extensive experience as CEO, ... and Fortune 500 companies within the molecular, clinical ... extensive marketing and sales experience within the pharmaceutical ...
(Date:12/7/2016)... "Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight" report by PNS ... in clinical pipeline. Currently 5 biosimilar version of Lantus are commercially available ... Kenya , Czech Republic , ... , Slovakia , United Kingdom ... on Lantus expired in 2014. Lantus is the brand name for ...
(Date:12/7/2016)... Dec. 7, 2016 KEY FINDINGS ... benefits such as reducing loss of blood during ... cardiac arrests, rapid recovery after surgeries, and decreasing ... be segmented into convective warming system, surface warming ... turn reduce the stay at hospitals thus, lowering ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... DrugDev again demonstrated its dedication ... one of the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department ... on both sides of the Atlantic with a mechanism to comply with EU data ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... (NYLF): Medicine will have the unique opportunity to get hands-on experience in ... high school students an immersive experience to gain invaluable, real-life medical skills that ...
(Date:12/7/2016)... ... 07, 2016 , ... "Today, MHA and mental health advocates ... systems reform legislation in more than fifty years. We applaud the bipartisan action ... elected officials to improving mental health services and supports in our nation. , ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Kenall Manufacturing, ... new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED luminaire that ... amount of light where and when it’s needed. , A 2’ x ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... in their bodies, a researcher at the Icahn School of Medicine at Mount ... The study found that when young children are exposed to secondhand marijuana smoke, ...
Breaking Medicine News(10 mins):